Bacman Sandra R, Gammage P A, Minczuk M, Moraes Carlos T
Department of Neurology, University of Miami School of Medicine, Miami, FL, United States.
CRUK Beatson Institute for Cancer Research, Glasgow, United Kingdom.
Methods Cell Biol. 2020;155:441-487. doi: 10.1016/bs.mcb.2019.12.004. Epub 2020 Jan 20.
Most patients with mitochondrial DNA (mtDNA) mutations have a mixture of mutant and wild-type mtDNA in their cells. This phenomenon, known as mtDNA heteroplasmy, provides an opportunity to develop therapies by selectively eliminating the mutant fraction. In the last decade, several enzyme-based gene editing platforms were developed to cleave specific DNA sequences. We have taken advantage of these enzymes to develop reagents to selectively eliminate mutant mtDNA. The replication of intact mitochondrial genomes normalizes mtDNA levels and consequently mitochondrial function. In this chapter, we describe the methodology used to design and express these nucleases in mammalian cells in culture and in vivo.
大多数线粒体DNA(mtDNA)突变患者的细胞中存在突变型和野生型mtDNA的混合物。这种现象被称为mtDNA异质性,为通过选择性消除突变部分来开发治疗方法提供了机会。在过去十年中,开发了几种基于酶的基因编辑平台来切割特定的DNA序列。我们利用这些酶开发了试剂,以选择性地消除突变的mtDNA。完整线粒体基因组的复制使mtDNA水平正常化,从而使线粒体功能正常化。在本章中,我们描述了在培养的哺乳动物细胞和体内设计和表达这些核酸酶所使用的方法。